Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339553
What this trial is testing
Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.
Who this might be right for
OvariancancerPlatinum-sensitive Recurrent
Peking University Third Hospital 30